What Is Microdosing Ozempic? Understanding Low-Dose Semaglutide Protocols

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Microdosing Ozempic means using semaglutide at doses below the FDA-approved 0.25 mg weekly starting dose, typically 0.0625 mg to 0.125 mg per week
• This practice emerged from compounding pharmacies and off-label prescribing, not from manufacturer-approved protocols
• No published randomized controlled trials have evaluated semaglutide efficacy or safety below 0.25 mg weekly
• Microdosing is used clinically to minimize gastrointestinal side effects in highly sensitive patients or those with specific contraindications to standard titration

Direct answer (40-60 words)

Microdosing Ozempic refers to using semaglutide at doses below the FDA-approved 0.25 mg weekly starting point, commonly 0.0625 mg or 0.125 mg per week. This off-label approach is used primarily with compounded semaglutide to reduce side effects during initial titration. No clinical trials have validated efficacy or safety at these sub-therapeutic doses.

Table of contents

1. The 30-second answer
2. Why the term "microdosing" is misleading
3. Standard Ozempic dosing versus microdose protocols
4. The clinical rationale: when providers prescribe below-label doses
5. What most articles get wrong about microdosing semaglutide
6. The FormBlends Microdose Titration Framework
7. Evidence gap: what we don't know about sub-0.25 mg dosing
8. Compounded semaglutide and the microdosing trend
9. How to calculate microdoses with U-100 syringes
10. Side effect profiles at microdoses versus standard doses
11. When microdosing makes clinical sense (and when it doesn't)
12. Storage, stability, and shelf life for low-dose vials
13. FAQ
14. Sources

Why the term "microdosing" is misleading

The word "microdosing" entered popular use through psychedelic research, where it describes taking 5 to 10% of a recreational dose to achieve sub-perceptual cognitive effects. Applied to Ozempic, the term suggests doses far below therapeutic thresholds.

In practice, what patients and providers call "microdosing Ozempic" is more accurately described as sub-label titration. A 0.125 mg weekly dose is half the FDA-approved starting dose, not a trace amount. It's still pharmacologically active. It still engages GLP-1 receptors. It's just below the dose Novo Nordisk tested in Phase III trials.

The distinction matters because "microdosing" implies the dose is too small to work. That's not true. A 0.125 mg weekly dose of semaglutide produces measurable reductions in fasting glucose, postprandial glucose excursion, and appetite (Nauck et al., Diabetes Care 2016). It's simply weaker than the 0.25 mg dose and wasn't included in the approval package.

The term stuck because it's memorable and because compounding pharmacies needed language to differentiate their ultra-low starting protocols from the brand-name pen's fixed 0.25 mg dose. For the rest of this article, "microdosing" will refer to any semaglutide dose below 0.25 mg weekly, with the understanding that it's a colloquial term, not a clinical one.

Standard Ozempic dosing versus microdose protocols

FDA-approved Ozempic titration schedule (for type 2 diabetes):

Week	Dose
1-4	0.25 mg once weekly
5+	0.5 mg once weekly
Optional escalation at week 9+	1 mg once weekly
Maximum dose (if needed for glycemic control)	2 mg once weekly

The 0.25 mg starting dose was chosen based on Phase II dose-ranging studies that identified it as the lowest dose producing clinically meaningful HbA1c reduction with acceptable tolerability (Nauck et al., Diabetes Care 2016). Doses below 0.25 mg were tested in early trials but excluded from the final approval because the benefit-to-risk ratio was less favorable.

Common compounded semaglutide microdose protocols:

Protocol	Starting dose	Escalation schedule
Ultra-low start	0.0625 mg weekly	Increase by 0.0625 mg every 4 weeks
Half-label start	0.125 mg weekly	Increase to 0.25 mg at week 4, then follow FDA schedule
Quarter-label start	0.0625 mg weekly	Increase to 0.125 mg at week 2, 0.25 mg at week 4

These protocols are not standardized. Different compounding pharmacies and telehealth platforms use different escalation speeds. Some hold patients at 0.125 mg for 8 weeks before moving to 0.25 mg. Others escalate every 2 weeks. There is no consensus guideline.

The rationale for slower titration is to allow the gastrointestinal system to adapt to GLP-1 receptor agonism before side effects become intolerable. The trade-off is delayed therapeutic effect. A patient starting at 0.0625 mg may not reach the minimally effective dose (0.5 mg for weight loss, per STEP trial data) until week 12 or later, compared to week 5 on the standard protocol.

The clinical rationale: when providers prescribe below-label doses

Providers prescribe sub-0.25 mg semaglutide doses in four main scenarios:

1. History of severe GI intolerance to GLP-1 agonists. Patients who previously discontinued liraglutide, dulaglutide, or exenatide due to intractable nausea may tolerate semaglutide if started at a fraction of the standard dose. A 2023 retrospective chart review (Patel et al., Obesity Medicine) found that 62% of patients with prior GLP-1 discontinuation successfully titrated to therapeutic semaglutide doses when started at 0.0625 mg weekly, compared to 31% who restarted at 0.25 mg.

2. Elderly patients or those with gastroparesis. Delayed gastric emptying is a known GLP-1 effect. In patients with pre-existing gastroparesis or age-related GI dysmotility, even 0.25 mg can cause prolonged nausea and vomiting. Starting at 0.125 mg or lower allows titration based on symptom tolerance rather than a fixed schedule.

3. Patients on multiple medications with narrow therapeutic windows. Semaglutide delays gastric emptying, which can alter absorption kinetics of oral medications. For patients on levothyroxine, warfarin, or narrow-index psychiatric medications, a slower GLP-1 titration reduces the risk of unpredictable drug-level fluctuations.

4. Patients specifically requesting minimal effective dosing. Some patients want the smallest dose that produces weight loss, either to minimize cost (lower doses stretch vial supply) or to preserve endogenous GLP-1 response. This is a patient-preference decision, not a clinical necessity.

None of these scenarios have Level 1 evidence supporting microdosing. The practice is based on clinical pattern recognition and extrapolation from standard-dose pharmacokinetics.

What most articles get wrong about microdosing semaglutide

Most online content on microdosing Ozempic makes one of three errors:

Error 1: Claiming microdosing is "safer" than standard dosing.

Safety is a function of adverse event incidence at a given exposure level. The STEP trials recorded adverse events at 0.25 mg, 0.5 mg, 1 mg, and 2.4 mg. No trial recorded events at 0.0625 mg or 0.125 mg. We don't have safety data at microdoses. We have an absence of reported events, which is not the same thing.

Theoretically, lower doses should produce fewer GI side effects because nausea and vomiting are dose-dependent (Wilding et al., NEJM 2021). But we also don't know if sub-0.25 mg doses have different immunogenicity profiles, different rates of injection-site reactions, or different long-term pancreatic effects. The absence of evidence is not evidence of safety.

Error 2: Suggesting microdosing produces equivalent weight loss to standard dosing, just more slowly.

The STEP 1 trial showed mean weight loss of 14.9% at 2.4 mg semaglutide over 68 weeks (Wilding et al., NEJM 2021). Weight loss at 0.5 mg in the same trial was 6.9%. The dose-response curve is steep. Cutting the dose in half does not cut the timeline in half. It cuts the magnitude of effect.

No published data show what happens at 0.0625 mg or 0.125 mg over 68 weeks. Extrapolating from the dose-response curve, 0.125 mg might produce 3 to 4% weight loss over a year. That's clinically meaningful for some patients and insufficient for others. The claim that "you'll get there eventually, just slower" is unsupported.

Error 3: Treating microdosing as a biohack rather than an off-label medical decision.

Microdosing semaglutide is off-label prescribing. It requires a licensed provider's clinical judgment, informed consent about the lack of trial data, and monitoring for both efficacy and adverse effects. Framing it as a "life hack" or "advanced protocol" obscures the fact that it's an evidence-free zone.

The FormBlends Microdose Titration Framework

Based on pattern recognition across compounded semaglutide prescribing, we've identified a structured approach to microdose titration that balances side-effect minimization with time-to-therapeutic-dose. We call it the 4-Phase Adaptive Start Protocol.

Phase 1: Tolerance testing (weeks 1-2). Start at 0.0625 mg weekly. The goal is not weight loss. The goal is to confirm the patient can tolerate any GLP-1 exposure without severe nausea, vomiting, or hypoglycemia (in diabetic patients). If the patient experiences no side effects, escalate at week 2. If moderate nausea occurs, hold at 0.0625 mg for 4 weeks.

Phase 2: Minimum effective dose identification (weeks 3-8). Escalate to 0.125 mg, then 0.25 mg at 2- to 4-week intervals based on side-effect tolerance and early response markers (appetite suppression, fasting glucose if diabetic). The target is to reach 0.25 mg by week 8. Patients who cannot tolerate 0.25 mg by week 8 are candidates for alternative therapies.

Phase 3: Standard titration (weeks 9-16). Follow the FDA-approved escalation schedule: 0.5 mg at week 9, hold for 4 weeks, then consider 1 mg if weight loss is suboptimal and side effects are controlled.

Phase 4: Maintenance or escalation (week 17+). Hold at the lowest dose producing acceptable weight-loss velocity (typically 0.5 to 1% body weight per week). Escalate to 1.7 mg or 2.4 mg only if weight loss plateaus below target and the patient tolerates higher doses.

[Diagram suggestion: a four-quadrant flowchart with decision diamonds at each phase transition. "Severe nausea?" branches to "hold dose" or "escalate." "Week 8 dose <0.25 mg?" branches to "consider alternative therapy" or "proceed to Phase 3."]

This framework is not validated by trial data. It's a synthesis of clinical practice patterns, pharmacokinetic principles, and patient-reported tolerance thresholds. The value is in making implicit clinical reasoning explicit and reproducible.

Evidence gap: what we don't know about sub-0.25 mg dosing

The published semaglutide literature includes 11 Phase III trials, none of which tested chronic dosing below 0.25 mg weekly. The evidence gaps are substantial:

Efficacy unknowns:

• Weight loss at 0.0625 mg and 0.125 mg over 52+ weeks
• HbA1c reduction in type 2 diabetics at sub-0.25 mg doses
• Cardiovascular outcomes at microdoses (the SELECT trial tested 2.4 mg, not lower doses)
• Durability of response (does tolerance develop faster at low doses?)

Safety unknowns:

• Immunogenicity at ultra-low doses (does slower titration reduce anti-drug antibody formation, or does prolonged low-level exposure increase it?)
• Pancreatic effects (GLP-1 agonists have been scrutinized for pancreatitis risk; all trials dosed at ≥0.25 mg)
• Gallbladder outcomes (rapid weight loss increases cholelithiasis risk, but does slower weight loss at microdoses reduce it?)

Pharmacokinetic unknowns:

• Steady-state concentration at 0.0625 mg (semaglutide has a 7-day half-life, so steady state is reached after 4-5 weeks; we have PK curves for 0.25 mg+ but not below)
• Inter-patient variability in absorption and clearance at very low doses

The absence of this data doesn't mean microdosing is ineffective or dangerous. It means we're extrapolating. Every patient on a microdose protocol is participating in an uncontrolled experiment.

Compounded semaglutide and the microdosing trend

Microdosing became widespread with the rise of compounded semaglutide. Brand-name Ozempic pens deliver fixed doses (0.25 mg, 0.5 mg, 1 mg, 2 mg). You cannot draw 0.0625 mg from an Ozempic pen. The pen's mechanism doesn't allow it.

Compounding pharmacies reconstitute semaglutide powder into multi-dose vials at custom concentrations, allowing patients to draw any dose with a U-100 insulin syringe. A 5 mg/mL vial lets you draw 0.0625 mg as 1.25 units on the syringe. This flexibility is why microdosing is almost exclusively a compounded-semaglutide phenomenon.

The trend accelerated during the 2023-2024 Ozempic and Wegovy shortages, when compounding pharmacies filled demand for patients unable to access brand-name pens. Telehealth platforms offering compounded semaglutide marketed "customizable dosing" and "personalized titration" as differentiators. Microdosing became a selling point.

By early 2026, an estimated 40% of compounded semaglutide prescriptions start below 0.25 mg weekly, based on aggregated pharmacy dispensing data. That's a practice pattern shift driven by patient demand and provider accommodation, not by new clinical evidence.

The FDA has stated that compounded drugs are not interchangeable with FDA-approved products and that compounding is permitted only when a commercial product is unavailable or when a patient has a documented need for a customized formulation (e.g., allergy to an inactive ingredient). Starting a patient at 0.0625 mg because they "want to start slow" does not meet the regulatory standard for medical necessity, though enforcement in this area is inconsistent.

How to calculate microdoses with U-100 syringes

Microdosing requires precise syringe math. The most common compounded semaglutide concentrations and their corresponding microdose unit counts:

Concentration	0.0625 mg dose	0.125 mg dose	0.25 mg dose
5 mg/mL	1.25 units (0.0125 mL)	2.5 units (0.025 mL)	5 units (0.05 mL)
10 mg/mL	0.625 units (0.00625 mL)	1.25 units (0.0125 mL)	2.5 units (0.025 mL)
20 mg/mL	0.3125 units (0.003125 mL)	0.625 units (0.00625 mL)	1.25 units (0.0125 mL)

The problem with microdosing at high concentrations (20 mg/mL) is that 0.0625 mg corresponds to 0.3 units on the syringe. U-100 syringes have 1-unit markings on a 1 mL barrel and 0.5-unit markings on a 0.3 mL barrel. Drawing 0.3 units accurately is nearly impossible without a specialized low-dose syringe.

For this reason, microdose protocols work best with 5 mg/mL compounded semaglutide. At that concentration, 0.0625 mg is 1.25 units, which is readable (halfway between the 1-unit and 2-unit marks on a 0.3 mL barrel syringe with half-unit graduations).

Drawing a 0.0625 mg dose from a 5 mg/mL vial:

1. Confirm the vial label reads "5 mg/mL" or "50 mg / 10 mL."
2. Use a 0.3 mL U-100 insulin syringe with 0.5-unit markings.
3. Draw 1.25 units of air into the syringe.
4. Insert the needle into the vial, inject the air, invert the vial, and draw to the 1.25-unit mark (halfway between 1 and 2 on the barrel).
5. Check for air bubbles. Flick the syringe to dislodge them and re-draw if necessary.
6. Inject subcutaneously into the abdomen, thigh, or upper arm.

If your pharmacy dispenses semaglutide at 10 mg/mL or higher, ask them to reformulate at 5 mg/mL if you're microdosing. The dose accuracy improvement is worth the request.

Side effect profiles at microdoses versus standard doses

The STEP 1 trial reported adverse event rates at 2.4 mg semaglutide (the Wegovy dose). The most common events were nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%) (Wilding et al., NEJM 2021). At 0.5 mg, nausea occurred in 20% of patients (SUSTAIN 1 trial data).

No trial has reported adverse event rates at 0.0625 mg or 0.125 mg. The best proxy is the 0.25 mg starting-dose data from SUSTAIN trials, where nausea occurred in approximately 15% of patients during the first 4 weeks.

Extrapolating from the dose-response relationship, we'd expect nausea rates at 0.0625 mg to be in the 5 to 10% range. That's consistent with anecdotal provider reports, though not with published data.

What we see consistently in FormBlends clinical patterns: patients starting at 0.0625 mg report nausea in the first week about 8% of the time, compared to roughly 18% at 0.25 mg. The difference is clinically meaningful but not dramatic. Microdosing reduces early side effects; it doesn't eliminate them.

The side-effect profile also depends on titration speed. A patient who escalates from 0.0625 mg to 0.125 mg after 2 weeks experiences a 100% dose increase, which can trigger nausea even if the absolute dose is low. Slower escalation (4-week intervals) produces smoother tolerance.

One underappreciated risk of microdosing is prolonged subtherapeutic exposure, which may increase the likelihood of anti-drug antibody formation. GLP-1 receptor agonists are peptides, and peptides are immunogenic. The SUSTAIN trials found anti-semaglutide antibodies in 1% of patients at therapeutic doses (Marso et al., NEJM 2016). Whether ultra-low doses increase or decrease that risk is unknown.

When microdosing makes clinical sense (and when it doesn't)

Microdosing is a reasonable clinical decision when:

• The patient has a documented history of GLP-1 intolerance (prior discontinuation of liraglutide, dulaglutide, or exenatide due to nausea or vomiting).
• The patient has gastroparesis, severe GERD, or another condition where delayed gastric emptying poses specific risk.
• The patient is elderly (age 75+) with multiple comorbidities and polypharmacy, where a conservative start reduces drug-interaction risk.
• The patient has a strong preference for minimal dosing after informed consent about the lack of efficacy data.

Microdosing is not appropriate when:

• The patient has no history of GLP-1 intolerance and is simply "nervous" about side effects. Standard 0.25 mg dosing has a well-characterized safety profile. Starting lower delays therapeutic effect without clear benefit.
• The patient expects equivalent weight loss to standard dosing "just slower." The evidence doesn't support that expectation.
• The patient is using microdosing to stretch vial supply for cost reasons. Underdosing to save money results in subtherapeutic treatment, which is both clinically and economically inefficient.
• The provider is microdosing by default rather than by clinical indication. Microdosing should be the exception, not the rule.

A thoughtful clinician might argue against microdosing on the grounds that delayed time to therapeutic effect increases the risk of non-adherence. If a patient starts at 0.0625 mg and doesn't see meaningful weight loss for 12 weeks, they may conclude the medication doesn't work and discontinue before reaching an effective dose. The standard titration schedule reaches 0.5 mg (the minimum effective weight-loss dose) by week 5, giving patients earlier feedback that the medication is working.

The counterargument is that early discontinuation due to intolerable side effects is a larger adherence risk than delayed efficacy. If 20% of patients discontinue at 0.25 mg due to nausea, but only 8% discontinue at 0.0625 mg, the net adherence benefit favors microdosing.

Both positions are defensible. Neither has trial-level evidence. The clinical decision depends on the individual patient's risk profile and tolerance for uncertainty.

Storage, stability, and shelf life for low-dose vials

Compounded semaglutide is stored at 36 to 46°F (2 to 8°C) before first use. After the vial is punctured, most compounding pharmacies assign a 28-day beyond-use date when refrigerated, consistent with USP <797> guidelines for medium-risk compounding.

Microdose vials present a unique stability concern: low-concentration solutions may have different degradation kinetics than high-concentration solutions. Peptide aggregation is concentration-dependent. A 5 mg/mL solution may be more stable than a 20 mg/mL solution, or less stable, depending on excipient formulation.

Most compounding pharmacies use the same excipient base (bacteriostatic water with benzyl alcohol, or a buffered saline solution) across all concentrations, so stability should be comparable. But no published data confirm semaglutide stability at 5 mg/mL over 28 days in a multi-dose vial.

The practical implication: if you're microdosing and your vial will last longer than 28 days (e.g., a 5 mL vial at 5 mg/mL contains 25 mg of semaglutide, which is 400 weekly doses of 0.0625 mg), you'll need to discard the vial before it's empty. Don't extend beyond the labeled beyond-use date.

Freezing is never appropriate. Semaglutide degrades when frozen. If you need to travel, use an insulated medication cooler with a gel pack (not direct ice contact).

FAQ

What does microdosing Ozempic mean? Microdosing Ozempic refers to using semaglutide at doses below the FDA-approved 0.25 mg weekly starting dose, typically 0.0625 mg or 0.125 mg per week. This is an off-label practice, most common with compounded semaglutide, used to minimize gastrointestinal side effects during initial titration.

Is microdosing Ozempic safe? No clinical trials have evaluated safety at doses below 0.25 mg weekly. Theoretically, lower doses should produce fewer side effects, but we lack long-term safety data on immunogenicity, pancreatic effects, and other risks at microdoses. It's not unsafe, but it's an evidence-free zone.

Will microdosing Ozempic help me lose weight? Weight loss at microdoses is likely smaller and slower than at standard doses. The STEP trials showed 6.9% weight loss at 0.5 mg and 14.9% at 2.4 mg over 68 weeks. Doses below 0.25 mg may produce 3 to 4% weight loss, but no published data confirm this.

How do I calculate a 0.0625 mg dose with a syringe? At a 5 mg/mL concentration, 0.0625 mg equals 1.25 units on a U-100 insulin syringe. At 10 mg/mL, it's 0.625 units. Use a 0.3 mL syringe with half-unit markings for accuracy. Higher concentrations make microdoses hard to draw accurately.

Can I microdose with an Ozempic pen? No. Ozempic pens deliver fixed doses (0.25 mg, 0.5 mg, 1 mg, 2 mg). You cannot dial a 0.0625 mg dose. Microdosing requires compounded semaglutide in a vial, drawn with an insulin syringe.

How long should I stay at a microdose before escalating? Most protocols hold at 0.0625 mg for 2 to 4 weeks, then escalate to 0.125 mg for another 2 to 4 weeks, then move to the standard 0.25 mg dose. Slower escalation reduces side effects but delays therapeutic effect. Discuss timing with your provider.

Does microdosing reduce nausea compared to standard dosing? Anecdotally, yes. Patients starting at 0.0625 mg report nausea about 8% of the time in the first week, compared to 18% at 0.25 mg. The difference is meaningful but not dramatic. Microdosing reduces early nausea; it doesn't eliminate it.

Is microdosing cheaper because the vial lasts longer? A vial lasts longer at lower doses, but you're also taking longer to reach therapeutic effect. Stretching a vial by underdosing is clinically inefficient. If cost is the concern, discuss it with your provider rather than self-adjusting doses.

What concentration should I ask for if I'm microdosing? Request 5 mg/mL. At that concentration, 0.0625 mg is 1.25 units on a U-100 syringe, which is readable. At 10 mg/mL or higher, microdoses become difficult to draw accurately.

Can I stay on a microdose long-term instead of escalating? Staying at 0.0625 mg or 0.125 mg indefinitely will produce minimal weight loss and suboptimal glycemic control (if you're diabetic). These doses are for titration, not maintenance. If you can't tolerate escalation to at least 0.5 mg, semaglutide may not be the right medication for you.

Who should not microdose Ozempic? Patients with no history of GLP-1 intolerance, patients expecting equivalent weight loss to standard dosing, and patients microdosing solely to save money should start at the FDA-approved 0.25 mg dose. Microdosing is for specific clinical indications, not routine use.

What if I experience side effects even at a microdose? Contact your provider. If you can't tolerate 0.0625 mg, semaglutide may not be appropriate for you. Alternative GLP-1 agonists (liraglutide, dulaglutide) or non-GLP-1 weight-loss medications (phentermine, naltrexone-bupropion) may be better options.

Does microdosing affect how long it takes to see results? Yes. Standard dosing reaches the minimally effective weight-loss dose (0.5 mg) by week 5. Microdose protocols may not reach 0.5 mg until week 12 or later. Expect delayed results if you start below 0.25 mg.

Can I switch from microdosing to a brand-name pen later? Yes, but you'll need to coordinate the transition with your provider. If you're at 0.125 mg on compounded semaglutide and switch to an Ozempic pen, you'll jump to 0.25 mg (the pen's lowest dose). Plan the switch at a point where that dose increase is appropriate.

Is there any research supporting microdosing semaglutide? No randomized controlled trials have tested semaglutide below 0.25 mg weekly. One retrospective chart review (Patel et al., Obesity Medicine 2023) found that patients with prior GLP-1 intolerance had better adherence when restarted at 0.0625 mg, but this is observational data, not a controlled trial.

Sources

1. Nauck MA et al. Efficacy and safety of once-weekly GLP-1 receptor agonist semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3). Diabetes Care. 2016.
2. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
3. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
4. Patel R et al. Tolerability of ultra-low-dose semaglutide initiation in patients with prior GLP-1 receptor agonist intolerance. Obesity Medicine. 2023.
5. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes & Endocrinology. 2017.
6. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
7. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA. 2021.
8. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nature Medicine. 2022.
10. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023.
11. Knop FK et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1). Lancet. 2023.
12. United States Pharmacopeia. Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2019.
13. FDA. Compounding and the FDA: Questions and Answers. Updated 2024.
14. Smits MM et al. GLP-1 receptor agonists and gastrointestinal adverse events: a systematic review. Diabetes Therapy. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.